Innoviva, Inc. is a pharmaceutical development company that operates in the US and abroad, with a history dating back to its incorporation in 1996. Some of its products include daily medicines for chronic obstructive pulmonary disease (COPD) and asthma, such as the combination treatments RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, that consist of various components such as inhaled corticosteroids. The company has also established key strategic partnerships such as with Sarissa Capital Management LP and Glaxo Group Limited to collaborate on creating new products.